260 related articles for article (PubMed ID: 30036867)
1. Eribulin in Heavily Pretreated Metastatic Breast Cancer Patients in the Real World: A Retrospective Study.
Pedersini R; Vassalli L; Claps M; Tulla A; Rodella F; Grisanti S; Amoroso V; Roca E; Simoncini EL; Berruti A
Oncology; 2018; 94 Suppl 1(Suppl 1):10-15. PubMed ID: 30036867
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of eribulin as first- to third-line treatment in patients with advanced or metastatic breast cancer previously treated with anthracyclines and taxanes.
Maeda S; Saimura M; Minami S; Kurashita K; Nishimura R; Kai Y; Yano H; Mashino K; Mitsuyama S; Shimokawa M; Tamura K;
Breast; 2017 Apr; 32():66-72. PubMed ID: 28056400
[TBL] [Abstract][Full Text] [Related]
3. Safety of eribulin as third-line chemotherapy in HER2-negative, advanced breast cancer pre-treated with taxanes and anthracycline: OnSITE study.
Manso L; Moreno Antón F; Izarzugaza Perón Y; Delgado Mingorance JI; Borrega García P; Echarri González MJ; Martínez-Jañez N; López-González A; Olier Garate C; Ballesteros García A; Chacón López-Muñíz I; Ciruelos Gil E; García-Sáenz JA; Paz-Ares L
Breast J; 2019 Mar; 25(2):219-225. PubMed ID: 30734437
[TBL] [Abstract][Full Text] [Related]
4. Phase II, Multicenter, Single-arm Trial of Eribulin as First-line Therapy for Patients With Aggressive Taxane-pretreated HER2-Negative Metastatic Breast Cancer: The MERIBEL Study.
Ortega V; Antón A; Garau I; Afonso N; Calvo L; Fernández Y; Martínez-García M; Blanco E; Zamora P; García M; Illarramendi JJ; Rodríguez Sánchez CA; Sampayo M; Aguirre E; Pérez-García JM; Cortés J; Llombart-Cussac A
Clin Breast Cancer; 2019 Apr; 19(2):105-112. PubMed ID: 30679100
[TBL] [Abstract][Full Text] [Related]
5. Phase II study of eribulin mesylate, a halichondrin B analog, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane.
Vahdat LT; Pruitt B; Fabian CJ; Rivera RR; Smith DA; Tan-Chiu E; Wright J; Tan AR; Dacosta NA; Chuang E; Smith J; O'Shaughnessy J; Shuster DE; Meneses NL; Chandrawansa K; Fang F; Cole PE; Ashworth S; Blum JL
J Clin Oncol; 2009 Jun; 27(18):2954-61. PubMed ID: 19349550
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of eribulin mesylate in patients with locally advanced or metastatic breast cancer previously treated with anthracycline/taxanes.
Chen L; Yan X; Luo T; Tian T; He P; Zhong X
Cancer Med; 2024 May; 13(10):e7295. PubMed ID: 38785215
[TBL] [Abstract][Full Text] [Related]
7. [Treatment Out Come of Eribulin in Patients with Advanced or Metastatic Breast Cancer Who Resistant to Anthracycline and Taxane].
Tanaka N; Ogura K; Hattori A; Inoue H; Yukawa H; Sakaguchi S; Matsuoka A; Kodera A; Naritaka Y; Hirano A
Gan To Kagaku Ryoho; 2017 Nov; 44(12):1200-1202. PubMed ID: 29394580
[TBL] [Abstract][Full Text] [Related]
8. Eribulin efficacy based on type of metastatic site: a real-life study in heavily pretreated metastatic breast cancer.
Prestifilippo A; Grippaldi D; Blanco G; Memeo L; Puliafito I; Giuffrida D
Future Oncol; 2017 Apr; 13(11s):5-10. PubMed ID: 28481186
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of eribulin in patients with locally advanced or metastatic breast cancer not meeting trial eligibility criteria: a retrospective study.
Iizumi S; Shimoi T; Tsushita N; Bun S; Shimomura A; Noguchi E; Kodaira M; Yunokawa M; Yonemori K; Shimizu C; Fujiwara Y; Tamura K
BMC Cancer; 2017 Dec; 17(1):819. PubMed ID: 29202787
[TBL] [Abstract][Full Text] [Related]
10. Tumour biology, metastatic sites and taxanes sensitivity as determinants of eribulin mesylate efficacy in breast cancer: results from the ERIBEX retrospective, international, multicenter study.
Dell'Ova M; De Maio E; Guiu S; Roca L; Dalenc F; Durigova A; Pinguet F; Bekhtari K; Jacot W; Pouderoux S
BMC Cancer; 2015 Oct; 15():659. PubMed ID: 26449988
[TBL] [Abstract][Full Text] [Related]
11. Ramucirumab With Eribulin Versus Eribulin in Locally Recurrent or Metastatic Breast Cancer Previously Treated With Anthracycline and Taxane Therapy: A Multicenter, Randomized, Phase II Study.
Yardley DA; Reeves J; Dees EC; Osborne C; Paul D; Ademuyiwa F; Soliman H; Guthrie T; Andersen J; Krekow L; Choksi J; Daniel B; Danso M; Favret A; Oommen S; Brufsky A; Bromund JL; Lin Y; Ibrahim AB; Richards PD
Clin Breast Cancer; 2016 Dec; 16(6):471-479.e1. PubMed ID: 27569274
[TBL] [Abstract][Full Text] [Related]
12. Multicentre, phase II study of eribulin in combination with S-1 in patients with advanced breast cancer.
Iwasa T; Tsurutani J; Watanabe S; Kato R; Mizuno Y; Kojima Y; Takashima T; Matsunami N; Morimoto T; Yamamura J; Ohtani S; Tanabe Y; Yoshinami T; Takano T; Komoike Y; Nakagawa K
BMC Cancer; 2019 Oct; 19(1):962. PubMed ID: 31619197
[TBL] [Abstract][Full Text] [Related]
13. Eribulin mesylate in advanced breast cancer: retrospective review of a single institute experience.
Martella F; Bacci C; Giordano C; Montagnani F; Gelain E; Rabatti L; Fioretto L
Future Oncol; 2015; 11(15 Suppl):31-6. PubMed ID: 26235263
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of eribulin monotherapy in patients with heavily pretreated metastatic breast cancer.
Ates O; Babacan T; Kertmen N; Sarici F; Cenoli A; Akin S; Karakas Y; Kilickap S; Ozisik Y; Sever AR; Aksoy S; Altundag K
J BUON; 2016; 21(2):375-81. PubMed ID: 27273947
[TBL] [Abstract][Full Text] [Related]
15. Eribulin as a Feasible and Safe Monotherapy in a Dialytic Pretreated Woman with Metastatic Breast Cancer: A Case Report.
Nettuno R; Menditto C
Oncology; 2018; 94 Suppl 1(Suppl 1):16-18. PubMed ID: 30036877
[TBL] [Abstract][Full Text] [Related]
16. Practical experiences with eribulin in patients with metastatic breast cancer.
Tesch H; Schneeweiss A
Anticancer Drugs; 2016 Feb; 27(2):112-7. PubMed ID: 26488444
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety evaluation of eribulin-trastuzumab combination therapy with heavily pretreated HER2-positive metastatic breast cancer.
Sarici F; Altundag K
J BUON; 2020; 25(6):2562-2569. PubMed ID: 33455097
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of eribulin in taxane-refractory patients in the 'real world'.
Lorusso V; Cinieri S; Latorre A; Porcu L; Del Mastro L; Puglisi F; Barni S
Future Oncol; 2017 May; 13(11):971-978. PubMed ID: 28326833
[TBL] [Abstract][Full Text] [Related]
19. Real-world efficacy and safety of eribulin in advanced and pretreated HER2-negative breast cancer in a Spanish comprehensive cancer center.
Sirvén MB; Fernández-Ortega A; Stradella A; Morilla I; Falo C; Vázquez S; Castany R; Villanueva R; Recalde S; Pérez VN; Gil-Gil M; Pernas S
BMC Pharmacol Toxicol; 2019 Nov; 20(1):68. PubMed ID: 31753013
[TBL] [Abstract][Full Text] [Related]
20. Predictive Factors of Eribulin Activity in Metastatic Breast Cancer Patients.
De Sanctis R; Agostinetto E; Masci G; Ferraro E; Losurdo A; Viganò A; Antunovic L; Zuradelli M; Torrisi RMC; Santoro A
Oncology; 2018; 94 Suppl 1(Suppl 1):19-28. PubMed ID: 30036884
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
